Karakayalı Muammer, Artac Inanç, Ilis Doğan, Omar Timor, Arslan Ayca, Guzel Ezgi, Karabag Yavuz, Rencuzogullari Ibrahim
Department of Cardiology, Kafkas University School of Medicine, Kars, Turkey.
Vasa. 2025 May;54(3):184-191. doi: 10.1024/0301-1526/a001178. Epub 2025 Jan 30.
Percutaneous superficial femoral interventions remain the preferred method of treatment for superficial femoral artery (SFA) disease. Nevertheless, long term restenosis continues to be a major limitation of percutaneous interventions. In this context, the objective of this study is to compare the efficacies of CHA2DS2-VASc, CHA2DS2-VASc-HS, ATRIA, ATRIA-HSV, and HATCH risk scoring systems in predicting long-term (5 years) restenosis due to percutaneous interventions to the superficial femoral artery. The sample of this retrospective study consisted of 545 peripheral artery disease (PAD) patients with a percutaneous intervention to the SFA. Of these patients, 362 and 183 were included in the group of PAD patients without long-term (5 years) SFA restenosis (Group 1) and in the group of PAD patients with long-term SFA restenosis (Group 2). The efficacies of CHA2DS2-VASc, CHA2DS2-VASc-HS, ATRIA, ATRIA-HSV, and HATCH risk scoring systems in predicting the development of long-term SFA restenosis were comparatively analyzed. CHA2DS2-VASc, CHA2DS2-VASc-HS, ATRIA, ATRIA-HSV, and HATCH risk scores all increased with long-term SFA restenosis. The receiver operating characteristic (ROC) curve analysis revealed that all five risk scoring systems successfully predicted long-term SFA restenosis, whereas the paired ROC curve analysis revealed that CHA2DS2-VASc-HS scores of >4 had the best prognostic power in predicting long term SFA restenosis. The study findings indicated that the CHA2DS2-VASc-HS score was an independent predictor of the development of SFA restenosis. The CHA2DS2-VASc-HS risk scoring system, which is the modified version of CHA2DS2-VASc, outperformed the CHA2DS2-VASc, HATCH, ATRIA, and ATRIA-HSV, the modified version of ATRIA, risk scoring systems in predicting long-term (5 years) SFA restenosis.
经皮股浅动脉介入治疗仍是股浅动脉（SFA）疾病的首选治疗方法。然而，长期再狭窄仍然是经皮介入治疗的主要限制因素。在此背景下，本研究的目的是比较CHA2DS2-VASc、CHA2DS2-VASc-HS、ATRIA、ATRIA-HSV和HATCH风险评分系统在预测经皮股浅动脉介入治疗导致的长期（5年）再狭窄方面的有效性。这项回顾性研究的样本包括545例接受SFA经皮介入治疗的外周动脉疾病（PAD）患者。其中，362例和183例分别纳入无长期（5年）SFA再狭窄的PAD患者组（第1组）和有长期SFA再狭窄的PAD患者组（第2组）。对CHA2DS2-VASc、CHA2DS2-VASc-HS、ATRIA、ATRIA-HSV和HATCH风险评分系统预测长期SFA再狭窄发生的有效性进行了比较分析。CHA2DS2-VASc、CHA2DS2-VASc-HS、ATRIA、ATRIA-HSV和HATCH风险评分均随长期SFA再狭窄而升高。受试者工作特征（ROC）曲线分析显示，所有五个风险评分系统均能成功预测长期SFA再狭窄，而配对ROC曲线分析显示，CHA2DS2-VASc-HS评分>4在预测长期SFA再狭窄方面具有最佳的预后能力。研究结果表明，CHA2DS2-VASc-HS评分是SFA再狭窄发生的独立预测因素。CHA2DS2-VASc-HS风险评分系统是CHA2DS2-VASc的改良版本，在预测长期（5年）SFA再狭窄方面优于CHA2DS2-VASc、HATCH、ATRIA以及ATRIA的改良版本ATRIA-HSV风险评分系统。
